Stock Report: Lannett Co. Inc. (LCI) Report Updated: May 20, 2013 | Print This Page

Lannett Company, Inc., together with its subsidiaries, develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. The company manufactures solid oral dosage forms, including tablets, capsules, and topical and oral solutions; and is pursuing partnerships and research contracts for the development and production of ophthalmic, nasal, and injectable products. It offers products for various medical indications comprising glaucoma, parkinson’s disease, migraine headache, antibiotic, anesthetic, endometriosis, irritable bowels, obesity, congestive heart failure, antipsychotic, diuretic, pain management, thyroid deficiency, dryness of the mouth, epilepsy, gout, bronchospasms, hypertension, and gallstone. The company markets its products under the brand names of Diamox, Symmetrel, Fiorinal, Fiorinal w/ Codeine #3, Cleocin, Danocrine, Bentyl, Tenuate, Dospan, Lanoxin, Adoxa, Periostat, Prolixin, Microzide, Hydrodiuril, Dilaudid, Levoxyl/Synthroid, Loxitane, Roxicodone, Adipex-P, Fastin, Salagen, Mysoline, Benemid, Rifadin, Brethine, Dyazide, and Actigall. It also offers active pharmaceutical ingredients. Lannett Company, Inc. sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company was founded in 1942 and is based in Philadelphia, Pennsylvania.